The KHENEREXT Study

NCT04604548 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Mitochondrial Diseases
Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Maternally Inherited Diabetes and Deafness (MIDD)
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
Chronic Progressive External Ophthalmoplegia (CPEO)

Interventions

DRUG: Oral administration of 100 mg KH176 twice daily

Sponsor

Khondrion BV

Collaborators

[object Object]
[object Object]
[object Object]